Spike Protein News and Research

RSS

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.

26 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

SARS-CoV-2 reprograms host chromatic network to induce immune dysfunction

A recent study conducted at the University of Texas Science Center, Houston, in the USA, has revealed that upon infection, SARS-CoV-2 alters the host chromatin architecture to suppress antiviral interferon-responsive genes and augment inflammatory genes. The study is currently available on the bioRxiv* preprint server.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.

22 Jul 2021

Scientist explore conserved RNA elements as potential targets for anti-SARS-CoV-2 drugs

The study, published in the journal Angewandte Chemie International Edition, identified many small molecules that bind to certain parts of the SARS-CoV-2 genome that are less likely altered by mutations using dedicated substance libraries. The scientists derived key functional units and groups in ligands for effective and safe targeting of SARS-CoV-2 RNA.

22 Jul 2021

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Some of these variants, known as variants of concern (VoC), have a much higher rate of transmission and increased mortality than the original SARS-CoV-2 strain. Therefore, it is imperative to assess the efficacy of the available vaccines against the circulating SARS-CoV-2 strains. In addition, tracking the continuously evolving genetic variants is also vital to prevent future outbreaks.

22 Jul 2021

Traditional Japanese dish may hold an answer to COVID-19

Natto, a fermented soybean dish often served for breakfast in Japan, originated at the turn of the last millennium but may hold an answer to a modern problem: COVID-19, according to a new study based on cell cultures.

21 Jul 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Study examines the host and viral factors that drive SARS-CoV-2 evolution

In a new paper recently uploaded to the preprint server bioRxiv*, two clinical isolates of SARS-CoV-2 are monitored by whole genome sequencing as they are passaged through several generations of Vero cells or human-derived primary nasal epithelial cells (PNEC), allowing direct observation of the occurrence of virus enhancing mutations and the way in which host cell factors shape virus evolution.

21 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Exhausted T cells linked to increased risk of COVID-19 mortality

New research led by Nadia R. Roan of Gladstone Institutes and the University of California, San Francisco, finds a correlation between high numbers of inflammatory CXCR4+ T cells and regulatory T cells specific to SARS-CoV-2 and dying from infection. In contrast, people who recovered from severe COVID-19 illness were more likely to have many SARS-CoV-2-specific T cells that perform homeostatic proliferation.

20 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine.

19 Jul 2021

Spike Protein News and Research

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

Variations in human ACE2 genetics associated with coronavirus susceptibility

Clinical trials during a pandemic – lessons from COVID-19

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

SARS-CoV-2 reprograms host chromatic network to induce immune dysfunction

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

Scientist explore conserved RNA elements as potential targets for anti-SARS-CoV-2 drugs

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Traditional Japanese dish may hold an answer to COVID-19

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Study examines the host and viral factors that drive SARS-CoV-2 evolution

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Exhausted T cells linked to increased risk of COVID-19 mortality

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News